BERKELEY HEIGHTS, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Genta Incorporated announced that Genasense(R) (oblimersen sodium) Injection, the Company’s lead anticancer compound, will be featured in multiple presentations at the 24th annual symposium of the Chemotherapy Foundation in New York, NY, and also at the 11th International Conference on Differentiation Therapy in Paris, France. Highlighted presentations include the following:
At the Chemotherapy Foundation Symposium: * Wednesday, November 8, 2006; 8:35 AM Oblimersen in Chronic Lymphocytic Leukemia: Long-term Follow-up on Minimal Residual Disease. Kanti R. Rai, M.D., Chief, Hematology and Oncology, North Shore/Long Island Jewish Medical Center, and Professor of Medicine, Albert Einstein College of Medicine. * Friday, November 10, 2006; 1:40 PM Oblimersen in Melanoma Update. Sanjiv Agarwala, M.D., Associate Medical Director of the Melanoma Program, Associate Professor of Medicine, and Associate Chief of the Division of Hematology-Oncology at the University of Pittsburgh Cancer Institute. At the International Conference on Differentiation Therapy: * Sunday, November 5, 2006; Modulation of Bcl-2 as a Strategy for Enhancing Apoptosis. Raymond P. Warrell, Jr., M.D., Chief Executive Officer, Genta Incorporated. About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company’s research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company’s lead compound from its oligonucleotide program. The Company has submitted a New Drug Application (NDA) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. Genta has additional randomized clinical trials ongoing in patients with acute myeloid leukemia, hormone- refractory prostate cancer, and lung cancer. The leading drug in Genta’s small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release and the presentations to follow may contain forward- looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:
* the Company’s ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration (“FDA”) or European Medicines Agency (“EMEA”); * the safety and efficacy of the Company’s products or product candidates; * the Company’s assessment of its clinical trials; * the commencement and completion of clinical trials; * the Company’s ability to develop, manufacture, license and sell its products or product candidates; * the Company’s ability to enter into and successfully execute license and collaborative agreements, if any; * the adequacy of the Company’s capital resources and cash flow projections, and the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations; * the adequacy of the Company’s patents and proprietary rights; * the impact of litigation that has been brought against the Company and its officers and directors; and * the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company’s Annual Report on Form 10-K for 2005 and its most recent quarterly report on Form 10-Q.
Genta Incorporated
CONTACT: Investor Relations, Tara Spiess or Andrea Romstad of TSCommunications Group, LLC, +1-908-286-3980, info@genta.com; or MediaRelations, Greg Tiberend of Richard Lewis Communications, Inc.,+1-212-827-0020
Web site: http://www.genta.com/
